Fosun International Ltd acquired a new position in shares of Becton Dickinson and Co (NYSE:BDX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,000 shares of the medical instruments supplier’s stock, valued at approximately $223,000.
Other large investors have also added to or reduced their stakes in the company. IndexIQ Advisors LLC acquired a new position in Becton Dickinson and during the fourth quarter worth about $25,000. Verus Capital Partners LLC bought a new stake in shares of Becton Dickinson and during the 4th quarter valued at approximately $27,000. Pinnacle Financial Partners Inc. acquired a new position in Becton Dickinson and during the 4th quarter worth approximately $31,000. Cedar Mountain Advisors LLC bought a new position in Becton Dickinson and in the 4th quarter valued at approximately $42,000. Finally, Raab & Moskowitz Asset Management LLC acquired a new stake in Becton Dickinson and in the fourth quarter valued at approximately $51,000. 86.79% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have recently issued reports on BDX shares. Morgan Stanley lowered their price target on shares of Becton Dickinson and from $271.00 to $255.00 and set an “equal weight” rating for the company in a report on Friday, March 27th. Stifel Nicolaus upped their target price on Becton Dickinson and from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wells Fargo & Co reissued a “buy” rating on shares of Becton Dickinson and in a research note on Friday, May 8th. Citigroup upped their price objective on Becton Dickinson and from $234.00 to $260.00 and gave the company a “neutral” rating in a research note on Friday, May 8th. Finally, SVB Leerink reiterated a “market perform” rating and issued a $262.00 price objective (up previously from $245.00) on shares of Becton Dickinson and in a report on Friday, May 8th. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $275.79.
NYSE:BDX traded up $0.31 on Friday, reaching $239.25. 11,783,270 shares of the stock traded hands, compared to its average volume of 1,932,654. The company has a current ratio of 0.98, a quick ratio of 0.66 and a debt-to-equity ratio of 0.80. Becton Dickinson and Co has a 1-year low of $197.75 and a 1-year high of $286.72. The company’s 50 day moving average is $253.35 and its 200-day moving average is $255.35. The firm has a market capitalization of $64.79 billion, a price-to-earnings ratio of 72.06, a price-to-earnings-growth ratio of 2.57 and a beta of 0.95.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.23. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. The company had revenue of $4.25 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Becton Dickinson and’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.59 earnings per share. On average, equities research analysts forecast that Becton Dickinson and Co will post 10.5 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $3.16 dividend on an annualized basis and a yield of 1.32%. Becton Dickinson and’s payout ratio is currently 27.05%.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: How To Calculate Debt-to-Equity Ratio
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.